Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

BACKGROUND: Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial. METHODS: The aim of this retrospective multicenter study wa...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Transl Med
Main Authors: Cortellini, Alessio, Vitale, Maria G., De Galitiis, Federica, Di Pietro, Francesca R., Berardi, Rossana, Torniai, Mariangela, De Tursi, Michele, Grassadonia, Antonino, Di Marino, Pietro, Santini, Daniele, Zeppola, Tea, Anesi, Cecilia, Gelibter, Alain, Occhipinti, Mario Alberto, Botticelli, Andrea, Marchetti, Paolo, Rastelli, Francesca, Pergolesi, Federica, Tudini, Marianna, Silva, Rosa Rita, Mallardo, Domenico, Vanella, Vito, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A.
格式: Artigo
語言:Inglês
出版: BioMed Central 2019
主題:
Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857130/
https://ncbi.nlm.nih.gov/pubmed/31730009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-02132-x
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍